The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
17 November 2026

CRISM Therapeutics Corporation
(‘CRISM’, ‘CRISM Therapeutics’ or the ‘Company’)
First patient successfully treated with ChemoSeed®
Significant milestone achieved
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that the first patient has been successfully treated with its proprietary irinotecan ChemoSeed® implant as part of the Company's registration grade Phase II clinical trial in patients with glioblastoma. This represents a significant milestone for CRISM Therapeutics, marking the commencement of clinical data generation for its lead oncology asset and the first step towards establishing the safety and efficacy profile of ChemoSeed® in a disease with significant unmet medical need.
The procedure, undertaken yesterday at University Hospitals Birmingham NHS Foundation Trust, the Company's lead NHS clinical trial site, involved implantation of ChemoSeed® into the tumour resection cavity, following surgical removal of recurrent glioblastoma. The surgical procedure was completed successfully, with ChemoSeed® implanted as planned and no reported procedural complications.
The Company is also pleased to report that the patient has remained clinically stable during the initial post-operative period, with no seizures reported following surgery. The patient will continue to undergo scheduled post-operative clinical and imaging assessments in accordance with the study protocol. The Company will provide further updates as appropriate following review of these assessments and as recruitment progresses.
Professor Christopher McConville, Chief Scientific Officer of CRISM Therapeutics, commented: "The successful treatment of our first patient with ChemoSeed® represents a landmark achievement for the Company and the culmination of many years of research, development and clinical preparation.
"We are delighted that the implantation procedure has been completed successfully and that ChemoSeed® has now progressed into clinical evaluation in patients. This is an important step towards generating the clinical evidence needed to establish the safety and potential efficacy of our technology.
"Our focus now turns to monitoring the patient's progress and continuing recruitment into the study. We would like to thank the clinical investigators, NHS Trust and our clinical development partners for their commitment and hard work in reaching this important milestone."
Professor, Garth Cruickshank, Medical Advisor for CRISM Therapeutics who was present during the surgical procedure, added: “Witnessing the first implantation of ChemoSeed® in a patient with recurrent glioblastoma was an important moment and represents a meaningful first step in demonstrating that ChemoSeed® can be incorporated into neurosurgical practice in a straightforward and well-tolerated manner.
"While further clinical follow-up will be essential to evaluate safety and tolerability, we are pleased with the successful completion of this first procedure and look forward to monitoring the patient's recovery and the subsequent clinical assessments."
-Ends-
Enquiries:
|
Company |
Nomad and Broker |
Financial PR |
|
CRISM Therapeutics Corporation |
S.P. Angel Corporate Finance LLP |
Burson Buchanan |
|
Andrew Webb, CEO Chris McConville, CSO |
David Hignell Vadim Alexandre Adam Cowl |
Henry Harrison Topham Jamie Hooper |
|
via Burson Buchanan |
+44 (0) 20 3470 0470 |
+44 (0) 20 7466 5000 |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
CRISM has treated its first patients and is actively recruiting at its lead NHS clinical trial site for its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma.
The Company is also developing docetaxel-ChemoSeed® for advanced prostate cancer, with pre-clinical data demonstrating a 58% reduction in tumour volume compared to systemic standard-of-care and no adverse tolerability effects observed.
For more information please visit: https://www.crismtherapeutics.com/
The Company's LEI is 213800XFW6MKVCHHPW88.